BRL 305
Alternative Names: BRL-305Latest Information Update: 24 Apr 2024
Price :
$50 *
At a glance
- Originator BRL Medicine
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastric cancer; Multiple myeloma
Most Recent Events
- 24 Apr 2024 Preclinical trials in Multiple myeloma in China (Parenteral), prior to April 2024 (BRL Medicine pipeline, April 2024)
- 15 Jul 2022 Preclinical trials in Gastric cancer in China (Parenteral) before July 2022 (BRL Medicine pipeline, July 2022)